
Masimo (MASI) Stock Forecast & Price Target
Masimo (MASI) Analyst Ratings
Bulls say
Masimo Corporation showcases a positive financial outlook supported by growth in its core SET pulse oximetry business and significant expansion in advanced monitoring parameters, including capnography and hemodynamics. The company is expected to achieve a notable EBIT margin increase, projected to reach 29.2% in FY26 and 29.8% in FY27, driven by both an expanding product portfolio and market share gains in key segments. Furthermore, the anticipated acceleration of total revenue growth, bolstered by new product launches and a strong international pulse oximetry market, reflects Masimo's strategic investment in innovation and market responsiveness.
Bears say
Masimo Corp faces significant financial headwinds, including an anticipated negative impact of $16M-$17M from tariffs in FY25, which is expected to adversely affect operating margins by approximately 110 basis points. Additional risks contributing to a negative outlook for the stock include heightened competition, potential delays in product regulatory approval, supply chain issues, and pricing pressures, all of which could hinder revenue growth and profitability metrics. Furthermore, reliance on hospital demand for capital equipment and fluctuating order timings has created uncertainty, resulting in a cautious revenue forecast that is likely to lead to unpredictable quarterly results.
This aggregate rating is based on analysts' research of Masimo and is not a guaranteed prediction by Public.com or investment advice.
Masimo (MASI) Analyst Forecast & Price Prediction
Start investing in Masimo (MASI)
Order type
Buy in
Order amount
Est. shares
0 shares